Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab versus risankizumab in moderately to severely active Crohn's disease
ISRCTN39379437Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3 trial of guselkumab and risankizumab in Crohn's disease (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Deep remission at Week 52. Started Apr 2026; status: recruiting.
02
Drugs
guselkumabrisankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ISRCTN39379437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN39379437.